Tekla Life Sciences Investors Strategic Asset Allocation Index
Tekla Life Sciences Investors strategic asset allocation index. Tekla Life Sciences Investors (HQL) has a Strategic Asset Allocation Index of 100.2% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $561.89 Million) total $561.89 Million, measured against net assets of $560.83 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Tekla Life Sciences Investors balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Tekla Life Sciences Investors (2006–2025)
Strategic asset allocation index of Tekla Life Sciences Investors from 2006 to 2025. This chart shows how Tekla Life Sciences Investors's Strategic Asset Allocation Index has evolved across 15 annual periods from 2006 to 2025. As of March 2026, the index stands at 100.2%, representing strategic assets of $561.89 Million against net assets of $560.83 Million USD. Check tangible equity quality of Tekla Life Sciences Investors to evaluate the tangible quality of the company's equity base.
Tekla Life Sciences Investors Strategic Asset Allocation Index by Year (2006–2025)
Tekla Life Sciences Investors strategic asset allocation index by year from 2006 to 2025. The table below presents the year-by-year Strategic Asset Allocation Index for Tekla Life Sciences Investors from 2006 to 2025, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see HQL company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 100.1% | $514.12 Million | $- | $514.12 Million | $513.66 Million | ▼ 0.0 pp |
| 2024 | 100.1% | $460.30 Million | $- | $460.30 Million | $459.69 Million | ▲ +1.2 pp |
| 2023 | 98.9% | $397.53 Million | $- | $397.53 Million | $401.93 Million | ▼ -5.2 pp |
| 2022 | 104.1% | $414.08 Million | $- | $414.08 Million | $397.90 Million | ▲ +2.0 pp |
| 2021 | 102.0% | $534.01 Million | $- | $534.01 Million | $523.44 Million | ▲ +1.9 pp |
| 2020 | 100.1% | $483.97 Million | $- | $483.97 Million | $483.57 Million | ▲ +0.8 pp |
| 2019 | 99.3% | $381.47 Million | $- | $381.47 Million | $384.16 Million | ▲ +1.2 pp |
| 2018 | 98.1% | $466.45 Million | $- | $466.45 Million | $475.49 Million | ▼ -2.0 pp |
| 2017 | 100.1% | $466.98 Million | $- | $466.98 Million | $466.35 Million | ▲ +10.8 pp |
| 2016 | 89.4% | $370.84 Million | $- | $370.84 Million | $414.97 Million | ▼ -6.5 pp |
| 2015 | 95.9% | $443.83 Million | $- | $443.83 Million | $462.84 Million | ▼ -3.2 pp |
| 2014 | 99.1% | $440.09 Million | $- | $440.09 Million | $444.09 Million | ▼ -0.9 pp |
| 2008 | 100.0% | $277.89 Million | $- | $277.89 Million | $277.80 Million | ▼ -0.2 pp |
| 2007 | 100.3% | $308.77 Million | $- | $308.77 Million | $308.00 Million | ▼ -0.2 pp |
| 2006 | 100.5% | $269.39 Million | $- | $269.39 Million | $268.10 Million | — |